Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Executive Summary

Attention to the departure of neurology reviewer Ron Farkas from FDA has focused on what it means for Sarepta’s eteplirsen application, but there are larger regulatory environment issues that deserve more scrutiny.


Related Content

Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications
Sarepta Complained To Woodcock About Exondys 51 Review Early And Often
Jenkins' Retirement From US FDA Was Several Years In The Making
Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Sarepta, FDA And The Dangers Of Strong Early Results


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts